AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Find Drugs in Development News & Deals for Tonabacase

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.


Lead Product(s): Tonabacase

Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Basilea Pharmaceutica

Deal Size: $CHECK CHECK Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.


Lead Product(s): Tonabacase

Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Basilea Pharmaceutica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.


Lead Product(s): Tonabacase

Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Basilea Pharmaceutica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY